Jacobiopharma

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

20 Chinese Companies to Watch in Q1 2023– Healthcare+

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

CAR-T Therapy Market Map in China

The market for cell therapy products such as CAR-T is expected to expand rapidly based on increasing investment from the industry and the implementation of advanced technologies.

China VC Investment List Q4 2022 – Healthcare

For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.

15 Companies to Watch in December 2022 — Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds and industry events that took place in China's healthcare space in December 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.

Is Domestic Substitution the Future Trend for the Chinese Cell Culture Media Market?

The cell culture media industry has developed rapidly in recent years, but foreign enterprises still dominate the Chinese market. Is Domestic substitution the future trend for the Chinese cell culture media market?

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the second part, we will list major M&A, product approvals, and strategic collaboration news. It's by no means exhaustive, but it'll shed some light on what's to come

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the first part, we will list major financing and IPO news. It's by no means exhaustive, but it'll shed some light on what's to come.

15 Companies to Watch in November 2022-Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in November 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.

Immunotherapy in China: A Rising Star in the Field of Cancer Treatment

Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.

Challenges and Opportunities Possessed by Digital Therapeutics Industry

Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.

15 Companies to Watch in October 2022-Healthcare

EqualOcean 2022 China AI Health 30 Companies list Reveals

Starting from September 2022, EqualOcean had been conducting deep market research and expert interviews aiming to select out 30 most representative China-based companies in the AI Health sector that are with the most growth and development potential. It is finally officially finalized, and we give our deep and sincere congratulations to those 30 companies and wish them all the best in the future.

Dissection of Applications of AI in China’s Healthcare Industry

As AI enables automatic problem-solving and is highly intelligence, it can be applied to a wide variety of fields in the healthcare, especially for the labour intensive tasks. In China, from the basic medical health records to the complex disease treatment planning and prediction, you can always find the involvement of AI. Here, we choose seven sectors with more mature development and introduced them.

China's Road to Tackle Autoimmune Diseases Globally

The market of autoimmune diseases medication is vast both in China and overseas and presents great opportunities. However, the number of Chinese players specializing in autoimmune diseases is limited. This article introduced the autoimmune diseases medication market in China and explained why Chinese players are limited then give some recommendations on what efforts Chinese companies can make to compete with western players.

China VC Investment List Q3 2022 – Healthcare

This is part of a seven-part series on China's VC investment in Q3 2022. This series features firms spanning seven industries, including automaking, healthcare, new consumption, intelligent hardware, smart manufacturing, enterprise services and emerging technologies.